RMC-6236 to advance to Ph 3 testing in pancreatic cancer following encouraging results from a Ph 1 study
“RMC-6236 is the first targeted investigational drug designed to directly inhibit all major forms of oncogenic RAS, the major drivers of PDAC. RMC-6236 has shown compelling anti-tumor activity and a favorable safety profile in a broad population of patients with previously treated PDAC, and has potential to become an important new treatment option. Extensive efforts are ongoing toward launching RASolute 302, a global, randomized Phase 3 clinical trial comparing RMC-6236 to chemotherapy as 2L treatment of patients with metastatic PDAC.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the